The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | EVI1 alteration in AML: mechanisms, disease risk & potential targeting
Transcription factor alterations in acute myeloid leukemia (AML) could be a key therapeutic target, as discussed here by Ruud Delwel, PhD, of the Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands. Dr Delwel discusses his group’s research into EVI1 and the mechanisms of its alteration in AML. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
